C4 Therapeutics Inc. (CCCC): Price and Financial Metrics

C4 Therapeutics Inc. (CCCC): $8.56

0.14 (+1.66%)

POWR Rating

Component Grades













Add CCCC to Watchlist
Sign Up

Industry: Biotech



in industry


  • Value is the dimension where CCCC ranks best; there it ranks ahead of 51.74% of US stocks.
  • The strongest trend for CCCC is in Stability, which has been heading up over the past 179 days.
  • CCCC ranks lowest in Momentum; there it ranks in the 8th percentile.

CCCC Stock Summary

  • C4 THERAPEUTICS INC's stock had its IPO on October 2, 2020, making it an older stock than merely 11.2% of US equities in our set.
  • With a year-over-year growth in debt of 288.16%, C4 THERAPEUTICS INC's debt growth rate surpasses 94.6% of about US stocks.
  • In terms of volatility of its share price, CCCC is more volatile than 93.49% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to C4 THERAPEUTICS INC, a group of peers worth examining would be CARA, AEVA, ANAB, PRTA, and CUE.
  • To check out C4 THERAPEUTICS INC's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001662579.

CCCC Valuation Summary

  • In comparison to the median Healthcare stock, CCCC's price/sales ratio is 66.67% higher, now standing at 8.
  • Over the past 26 months, CCCC's EV/EBIT ratio has gone up 24.5.

Below are key valuation metrics over time for CCCC.

Stock Date P/S P/B P/E EV/EBIT
CCCC 2022-11-25 8.0 1.2 -3.6 -4.1
CCCC 2022-11-23 8.0 1.2 -3.6 -4.0
CCCC 2022-11-22 9.5 1.4 -4.3 -4.7
CCCC 2022-11-21 9.7 1.5 -4.4 -4.8
CCCC 2022-11-18 9.8 1.5 -4.4 -4.9
CCCC 2022-11-17 9.7 1.5 -4.4 -4.8

CCCC's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CCCC has a Quality Grade of C, ranking ahead of 44.43% of graded US stocks.
  • CCCC's asset turnover comes in at 0.089 -- ranking 273rd of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows CCCC's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.089 1 -0.411
2020-12-31 0.128 1 -0.657

CCCC Price Target

For more insight on analysts targets of CCCC, see our CCCC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $61.33 Average Broker Recommendation 1.44 (Moderate Buy)

CCCC Stock Price Chart Interactive Chart >

Price chart for CCCC

CCCC Price/Volume Stats

Current price $8.56 52-week high $38.05
Prev. close $8.42 52-week low $4.84
Day low $8.01 Volume 265,000
Day high $8.60 Avg. volume 643,665
50-day MA $8.80 Dividend yield N/A
200-day MA $11.44 Market Cap 419.07M

C4 Therapeutics Inc. (CCCC) Company Bio

C4 Therapeutics, Inc. provides new class of targeted protein degradation. It develops Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Cambridge, MA.

CCCC Latest News Stream

Event/Time News Detail
Loading, please wait...

CCCC Latest Social Stream

Loading social stream, please wait...

View Full CCCC Social Stream

Latest CCCC News From Around the Web

Below are the latest news stories about C4 THERAPEUTICS INC that investors may wish to consider to help them evaluate CCCC as an investment opportunity.

The past year for C4 Therapeutics (NASDAQ:CCCC) investors has not been profitable

As every investor would know, you don't hit a homerun every time you swing. But it should be a priority to avoid...

Yahoo | November 13, 2022

Wells Fargo Keeps Their Hold Rating on C4 Therapeutics (CCCC)

In a report released today, Derek Archila from Wells Fargo maintained a Hold rating on C4 Therapeutics (CCCC - Research Report), with a price target of $11.00. The company's shares closed yesterday at $8.86.Archila covers the Healthcare sector, focusing on stocks such as Ascendis Pharma, Incyte, and Blueprint Medicines. According to TipRanks, Archila has an average return of 1.6% and a 38.87% success rate on recommended stocks. C4 Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $25.67, a 189.73% upside from current levels. In a report released on November 4, J.P. Morgan also downgraded the stock to a Hold with a $15.00 price target.

Ryan Adist on TipRanks | November 8, 2022

Wall Street Analysts Think C4 Therapeutics, Inc. (CCCC) Could Surge 227%: Read This Before Placing a Bet

The consensus price target hints at a 227.3% upside potential for C4 Therapeutics, Inc. (CCCC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Yahoo | November 8, 2022

C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Lags Revenue Estimates

C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of 0% and 30.52%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 3, 2022

C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights

The Phase 1/2 Clinical Trials of CFT7455, an IKZF1/3 MonoDAC™ Degrader, and CFT8634, a BRD9 BiDAC™ Degrader, Continue to Enroll Patients and Advance Through Dose Escalation IND Clearance Achieved for CFT1946, a BRAF-V600 BiDAC Degrader; On Track to Initiate the Phase 1/2 Clinical Trial by Year-End Cash, Cash Equivalents and Marketable Securities Total $366.0 million as of September 30, 2022; Expected to Provide Runway to End of 2024 WATERTOWN, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- C4 Therapeu

Yahoo | November 3, 2022

Read More 'CCCC' Stories Here

CCCC Price Returns

1-mo -3.93%
3-mo N/A
6-mo 14.75%
1-year -74.83%
3-year N/A
5-year N/A
YTD -73.42%
2021 -2.81%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.6205 seconds.